Search Results

/or potential risk of cancer in family members. If these criteria are met, germline multigene testing should include at least BRCA1 , BRCA2 , ATM , PALB2 , CHEK2 , MLH1 , MSH2 , MSH6 , and PMS2 . Posttest genetic counseling is strongly recommended if

.2013 to Version 1.2015 to reflect the most recent updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer. This update includes many important changes and additions, such as addressing genetic counseling as part of

-stage breast cancer changed their preferences after a medical consultation. Choice-based techniques such as discrete choice experiments (DCE) 4 have been successfully used to evaluate genetic counseling for cancer, 5 screening programs, 6 and cancer

example in a condition known as ‘mosaicism,’ in which the mutation is not present in all of the cells of the body). Because of this, the NCCN Guidelines continue to highlight the critical importance of genetic counseling for patients prior to undergoing

mother and/or father. 1 , 2 An individual suspected of being at risk for hereditary cancer should be offered genetic counseling. 3 , 4 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast

cancer care continuum, including navigation, chemotherapy toxicity management, genetic counseling, clinical trial enrollment, mental health services, survivorship care, and palliative care ( Figure 1 ). 6 – 8 Guidelines need to evolve to offer evidence

definitively rule this out, because it would have implications for treatment and genetic counseling. Because blood could not be used in this instance as a source of germline DNA, we performed Sanger sequencing using DNA extracted from a buccal swab

these NCCN Guidelines, visit NCCN.org ). 17 The NCCN Guidelines also recommend genetic counseling for patients who are considering p53 testing. 17 A multidisciplinary approach with professional geneticists, counselors, psychologists, and oncologists

treatment should not be delayed for genetic counseling. For patients with recurrent or refractory disease, validated molecular testing should be performed in a CLIA-approved facility using the most recently obtained tissue. Testing for patients with

Fleisher L Roussi P . Facilitating informed decision making about breast cancer risk and genetic counseling among women calling the NCI's Cancer Information Service . J Health Commun 2005 ; 10 ( Suppl ): S119 – 136 . 21. Ellis PM . Attitudes